Tuberculosis in Specific Conditions

Nihat SAPANa , Merve KORKMAZb

aBursa Uludağ University Faculty of Medicine, Department of Pediatric Immunology and Allergy Diseases, Bursa, Türkiye
bBursa Uludağ University Faculty of Medicine, Department of Pediatric Chest Diseases, Bursa, Türkiye

ABSTRACT
Tuberculosis (TB) remains to be an important health issue worldwide. In accordance with data from Ministry of Health, children aged 0-14 years account for 6% of all TB cases. Pediatric TB may present with varying manifestations. Diagnosis of TB in children is challenging, with additional challenges in arrangement of treatment and compliance to treatment, as well as regarding allergic reaction or resistance to drugs. In this article, information is given about situations when tuberculosis treatment needs to be extended, when corticosteroids need to be added, how to proceed when drug side effects occur, and how to shape the treatment in organ failure.
Keywords: Antitubercular agents; isoniazid

Referanslar

  1. Çocukluk Çağı Tüberkülozu. TC. Sağlık Bakanlığı Tüberküloz Tanı ve Tedavi Rehberi. Sağlık Bakanlığı Yayın no: 862, 2019. p. 148-9.
  2. Yazan H, Çakır E. Çocuklarda akciğer tüberkülozu. Gülen F, editör. Çocukluk Çağı, Solunum Yolu Enfeksiyonları. 1. Baskı. Ankara:Türkiye Klinikleri; 2021. p.50-65.
  3. Tüberküloz Dairesi Başkanlığı- Halk Sağlığı Genel Müdürlüğü [Link]
  4. WHO 2022 global report. Graham SM, Cuevas LE, Jean-Philippe. [Link]
  5. Molla Kafi H, Çakır E. Çocukluk çağı tüberkülozunda olağan dışı durumlar. Özdemir A, editör. Çocuk Göğüs Hastalıklarında Zor Konular. 1. Baskı. Ankara: Türkiye Klinikleri; 2023. p. 8-13.
  6. Jenkins HE, Yuen CM. The burden of multidrug-resistant tuberculosis in children. Int J Tuberc Lung Dis. 2018;22(5):3-6. . [Crossref]  [PubMed]  [PMC]
  7. Maphalle LNF, Michniak-Kohn BB, Ogunrombi MO, Adeleke OA. Pediatric Tuberculosis Management: A Global Challenge or Breakthrough? Children (Basel). 2022;9(8):1120. [Crossref]  [PubMed]  [PMC]
  8. Seddon JA, Johnson S, Palmer M, van der Zalm MM, Lopez-Varela E, Hughes J, et al. Multidrug-resistant tuberculosis in children and adolescents: current strategies for prevention and treatment. Expert Rev Respir Med. 2021;15(2):221-37. [Crossref]  [PubMed]
  9. World Health Organisation. Guidance for national tuberculosis programmes on the management of tuberculosis in children WHO/ HTM/TB/2006.371, WHO/FCH/CAH/2006.7.
  10. Kumarvelu S, Prasad K, Khosla A, Behari M, Ahuja GK. Randomized controlled trial of dexamethasone in tuberculous meningitis. Tuber Lung Dis. 1994;75(3):203-7. [Crossref]  [PubMed]
  11. WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update.
  12. Vasakova M. Challenges of antituberculosis treatment in patients with difficult clinical conditions. Clin Respir J. 2015;9(2):143-52. [Crossref]  [PubMed]
  13. Ramappa V, Aithal GP. Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management. J Clin Exp Hepatol. 2013;3(1):37-49. [Crossref]  [PubMed]  [PMC]
  14. Oğuz Kayaalp. Tüberküloz ve diğer mikobakteri infeksiyonlarında kullanılan ilaçlar. In: Tıbbi Farmakoloji. 2002. s. 306-12.
  15. Schaaf HS, Thee S, van der Laan L, Hesseling AC, Garcia-Prats AJ. Adverse effects of oral second-line antituberculosis drugs in children. Expert Opin Drug Saf. 2016;15(10):1369-81. [Crossref]  [PubMed]
  16. Cevaal PM, Bekker LG, Hermans S. TB-IRIS pathogenesis and new strategies for intervention: Insights from related inflammatory disorders. Tuberculosis (Edinb). 2019;118:101863. [Crossref]  [PubMed]
  17. Falzon D, Schünemann HJ, Harausz E, González-Angulo L, Lienhardt C, Jaramillo E, et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J. 2017;49(3):1602308. [Crossref]  [PubMed]  [PMC]
  18. Ersöz Doğru D. Özel Durumlarda Tüberküloz Tedavisi. Turkiye Klinikleri J Pediatr Sci 2016;12(3):75-8.
  19. Frieden TR, Sterling TR, Munsiff SS, Watt CJ, Dye C. Tuberculosis. Lancet. 2003;362(9387):887-99. [Crossref]  [PubMed]